MedTrace Logo

Ovarian Laser Treatment in Women With Polycystic Ovarian Syndrome: A Randomized Study on the Laser Dose

NCT00643708 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2008-03-26

No results posted yet for this study

Summary

BACKGROUND: A new effective way, transvaginal ultrasound-guided ovarian interstitial laser-coagulation treatment, in management of anovulation in patients with polycystic ovary syndrome (PCOS), has been presented in the data published. But, the optimal number of laser coagulation points in the ovarian interstitial to be applied at the procedure is unclear. This clinic trial aims to explore an optimal laser dose for this new protocol. METHODS: Fifty-six PCOS women with clomifene citrate-resistant underwent ultrasound-guided transvaginal ovarian interstitial YAG-laser treatment. By random list table，all subjects were randomly divided into four groups in terms of the number of laser coagulation points made in their ovaries as follows: group A, one coagulation point per ovary; group B, two points; group C, three points; group D, four to five points. The size of each point was about 10 mm in diameter on the ovarian plane monitored by transvaginal ultrasound. Postoperative ovulation rate, pregnancy rate and some biochemical parameters were compared among four groups.

Conditions

Interventions

PROCEDURE

ovarian interstitial laser treatment

Different dose of laser: group A, one point per ovary.

PROCEDURE

ovarian interstitial laser treatment

Different dose of laser: group B, two points per ovary.

PROCEDURE

ovarian interstitial laser treatment

Different dose of laser: group c, three points per ovary.

PROCEDURE

ovarian interstitial laser treatment

Different dose of laser: group D, four-five points per ovary.

Sponsors & Collaborators

  • Shen-Zhen City Maternity and Child Healthcare Hospital

    lead OTHER

Principal Investigators

  • Wen-Jie Zhu, Master · Shen-Zhen City Maternity and Child Healthcare Hospital

Eligibility

Min Age
23 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00643708 on ClinicalTrials.gov